GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy

• Published in: Translational lung cancer research Vol. 9; no. 5; pp. 2008 - 2015
• Main Authors: Zhou, Qing, Chen, Ming, Wu, Gang, Chang, Jian-Hua, Jiang, Ou, Cui, Jiu-Wei, Han, Guang, Lin, Qin, Fang, Jian, Chen, Gong-Yan, Wu, Yi-Long
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 01.10.2020
• Subjects: Study Protocol; clinical trial; Programmed death ligand-1 (PD-L1); non-small cell lung cancer (NSCLC); phase III; consolidation therapy

In China, platinum-based doublet chemotherapy is the standard treatment for patients who have unresectable stage III non-small cell lung cancer (NSCLC), administered with radiotherapy on either a concurrent or sequential basis. However, NSCLC patients who undergo this treatment can expect poor media...